{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:24Z","timestamp":1793041224112,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacadv.2024.101126","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:23:30Z","timestamp":1722889410000},"page":"101126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P1","title":["Polypharmacy and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With Heart\u00a0Failure"],"prefix":"10.1016","volume":"3","author":[{"given":"Chukwuma","family":"Onyebeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-4458","authenticated-orcid":false,"given":"David","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahad","family":"Musse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musarrat","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika M.","family":"Safford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-3737","authenticated-orcid":false,"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacadv.2024.101126_bib1","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American heart association Joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101126_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2024.101126_bib3","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.amjcard.2011.02.322","article-title":"Patterns and Predictors of evidence-based medication Continuation among hospitalized heart failure patients (from Get with the guidelines\u2013heart failure)","volume":"107","author":"Krantz","year":"2011","journal-title":"Am J Cardiol"},{"issue":"10367","key":"10.1016\/j.jacadv.2024.101126_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101126_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/CIRCHEARTFAILURE.113.000132","article-title":"Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population?","volume":"7","author":"Bermingham","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101126_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","article-title":"Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease","volume":"155","author":"Ho","year":"2008","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cardfail.2013.11.006","article-title":"Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation","volume":"20","author":"Eapen","year":"2014","journal-title":"J\u00a0Card Fail"},{"issue":"15","key":"10.1016\/j.jacadv.2024.101126_bib8","article-title":"Reasons for guideline nonadherence at heart failure discharge","volume":"7","author":"Gilstrap","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101126_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ejheart.2008.08.001","article-title":"Cardiologists\u2019 awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey","volume":"10","author":"Erhardt","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101126_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0b013e3182a3e525","article-title":"Reasons for not prescribing guideline-recommended medications to adults with heart failure","volume":"51","author":"Steinman","year":"2013","journal-title":"Med Care"},{"issue":"5-6","key":"10.1016\/j.jacadv.2024.101126_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-017-6764-8","article-title":"Barriers to beta-blocker Use and up-titration among patients with heart failure with reduced ejection fraction","volume":"31","author":"Levitan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101126_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1543-5946(10)80007-8","article-title":"A\u00a0taxonomy of reasons for not prescribing guideline-recommended medications for patients with heart failure","volume":"8","author":"Steinman","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2125.2007.02961.x","article-title":"OLDY (OLd people Drugs & dYsregulations) Study Group. Relationship between polypharmacy and underprescribing","volume":"65","author":"Kuijpers","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101126_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00228-014-1651-8","article-title":"Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from the Irish LongituDinal Study on Ageing study (TILDA)","volume":"70","author":"Galvin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jacadv.2024.101126_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jchf.2023.03.007","article-title":"Polypharmacy and optimization of guideline-directed medical therapy in heart failure","volume":"11","author":"Khan","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.jacadv.2024.101126_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0735-1097(19)31396-8","article-title":"Polypharmacy increases in prevalence and Severity following a heart failure hospitalization","volume":"73","author":"Unlu","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101126_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jacadv.2024.101126_bib19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib20","first-page":"339","article-title":"Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction","volume":"7","author":"Enzan","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/eurheartj\/ehx663","article-title":"Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: Deja-vu all over again?","volume":"39","author":"Wilcox","year":"2018","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2024.101126_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jacc.2013.09.070","article-title":"Frailty assessment in the cardiovascular care of older adults","volume":"63","author":"Afilalo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-1058-7","article-title":"Prevalence and determinants of hyperpolypharmacy in adults with heart failure: an observational study from the national Health and Nutrition Examination survey (NHANES)","volume":"19","author":"Kennel","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101126_bib24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jacadv.2024.101126_bib25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2024.101126_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101126_bib27","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the Diagnosis and management of patients with stable Ischemic heart disease","volume":"60","author":"Fihn","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101126_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.09.005","volume":"74","author":"Calkins","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jacadv.2024.101126_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of \u03b2-blocker therapy for patients with heart failure: a Quantitative Overview of Randomized trials","volume":"164","author":"Ko","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","author":"Thomas","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101126_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.jacadv.2024.101126_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal Insufficiency due to angiotensin converting enzyme inhibitors in Hypertensive Nephrosclerosis","volume":"115","author":"Toto","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101126_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators","volume":"131","author":"Kostis","year":"1996","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0735-1097(98)00656-1","article-title":"Use of sildenafil (Viagra) in patients with cardiovascular disease","volume":"33","author":"Cheitlin","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101126_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Ertram","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101126_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12459","article-title":"Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population","volume":"36","author":"Jonsson","year":"2018","journal-title":"Cardiovasc Ther"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101126_bib37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrcardio.2011.128","article-title":"Managing adverse effects and drug\u2013drug interactions of antiplatelet agents","volume":"8","author":"Kalyanasundaram","year":"2011","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/asheducation-2018.1.432","article-title":"Breadth of complications of long-term oral anticoagulant care","volume":"2018","author":"Ageno","year":"2018","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.jacadv.2024.101126_bib39","first-page":"208","article-title":"A\u00a0framework for the study of access to medical care","volume":"9","author":"Aday","year":"1974","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jacadv.2024.101126_bib40","doi-asserted-by":"crossref","unstructured":"Royston P, White IR. Multiple imputation by chained equations (MICE): implementation in stata. J Stat Softw, 45(4), 1-20.","DOI":"10.18637\/jss.v045.i04"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101126_bib41","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2019.08.007","article-title":"Prescribing patterns of heart failure-Exacerbating medications following a heart failure hospitalization","volume":"8","author":"Goyal","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.jacadv.2024.101126_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2018.07.096","article-title":"Prevalence and determinants of hyperpolypharmacy in adults with heart failure","volume":"24","author":"Kennel","year":"2018","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101126_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-021-01868-z","article-title":"Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients","volume":"21","author":"Parajuli","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.jacadv.2024.101126_bib45","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ejhf.2283","article-title":"Clinical inertia and medical therapy for heart failure: the unintended harms of \u2018first, do no harm.\u2019","volume":"23","author":"Greene","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101126_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchf.2021.12.004","article-title":"Frailty, guideline-directed medical therapy, and outcomes in HFrEF from the GUIDE-IT trial","volume":"10","author":"Shahzeb Khan","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"17","key":"10.1016\/j.jacadv.2024.101126_bib47","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","article-title":"Domain management Approach to heart failure in the geriatric patient: present and future","volume":"71","author":"Gorodeski","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24003211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24003211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:18:50Z","timestamp":1726705130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24003211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2772963X24003211"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101126","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101126"}}